GE Healthcare has pledged its support and technology to a national £55m ($86m) Cell Therapy manufacturing centre in Stevenage, UK, set to launch in 2017.
GE Healthcare and iBio are in talks about future projects after confirming they are working on a plant-based vaccine manufacturing site for Brazilian drugmaker Fiocruz/Bio-Manguinhosin.
GE Healthcare has started designing a vaccine manufacturing facility for an unnamed drug company, just days after expanding its collaboration with plant-cell production technology firm iBio.
GE Healthcare hopes its new modular validation platform (MVP) will change the way drugmakers think about how they create new plants and bring existing manufacturing facilities up to code.
GE Healthcare has snapped up specialist in disposable manufacturing
technologies Wave Biotech, adding a host of new products and
services for the biopharmaceutical manufacturing sector to its
catalogue.
Mar Cor Purification has bought GE Water and Process Technologies'
dialysis water business for $30.6m (€22.8m) to become the largest
provider of dialysis water in the US, and plans to expand their
presence in industrial life...
General Electric (GE) has launched a range of
ultra-high-performance plastics that it claims will answer the need
for cost-effective injection moldable resin.
GE Healthcare has launched a new contract offering that it claims
will cut the cost of running the service operations in life science
R&D labs by up to 20 per cent, at a time when pharma and
biotech firms are facing intense cost...
GE Healthcare has expanded its AKTA range of chromatography amd
filtration systems with the launch of AKTAcrossflow for membrane
selection and process development at the research scale.
GE Healthcare has launched two new products designed to meet
growing industry needs for the purification of monoclonal
antibodies, one of the fastest growing drug classes in the drug
industry.
GE Infrastructure, a business unit of General Electric, is to
acquire US water purification and wastewater treatment company
Ionics for around $1.1 billion (€813m), plus the assumption of
debt.
General Electric is the company offering to buy Amersham of the UK,
it was confirmed today. The US group is offering £5.7 billion for
the life sciences group, and said it has no plans to hive off
Biosciences.
